Erythrocyte Inosine triphosphatase activity: A potential biomarker for adverse events during combination antiretroviral therapy for HIV

N. Chantal Peltenburg, Jorgen Bierau, Jaap A. Bakker, Jolanda A. Schippers, Selwyn H. Lowe, Aimee D. C. Paulussen, Bianca J. C. van den Bosch, Mathie P. G. Leers, Bettina E. Hansen, Annelies Verbon

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Article numbere0191069
Number of pages14
JournalPLOS ONE
Volume13
Issue number1
DOIs
Publication statusPublished - 12 Jan 2018

Keywords

  • HUMAN-IMMUNODEFICIENCY-VIRUS
  • RIBAVIRIN-INDUCED ANEMIA
  • CHRONIC HEPATITIS-C
  • REVERSE-TRANSCRIPTASE
  • ITPA GENE
  • PYROPHOSPHOHYDROLASE DEFICIENCY
  • INFECTED PATIENTS
  • POLYMORPHISMS
  • INHIBITION
  • VARIANTS
  • Humans
  • Middle Aged
  • Male
  • HIV Infections/drug therapy
  • Young Adult
  • Anti-HIV Agents/administration & dosage
  • Erythrocytes/enzymology
  • Aged, 80 and over
  • Adult
  • Biomarkers/blood
  • Female
  • Pyrophosphatases/blood
  • Aged
  • Drug Therapy, Combination

Cite this